Results 271 to 280 of about 86,919 (334)

The formation of thromboplastin in human blood

The Journal of Physiology, 1953
Rosemary Biggs, A. S. Douglas, R. G. Macfarlane   +2 more
openaire   +3 more sources

High‐Dose Phenprocoumon Intoxication Treated With Therapeutic Plasma Exchange

Journal of Clinical Apheresis, Volume 40, Issue 5, October 2025.
Lea U. Krauß, Andreas M. Brosig, Patricia Mester, Tanja Elger, Stephan Schmid, Martina Müller, Vlad Pavel   +6 more
wiley   +1 more source

Target Trial Emulations of GLP‐1 and Dual GLP‐1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes

Liver International, Volume 45, Issue 10, October 2025.
ABSTRACT Background Clinical trials suggest GLP‐1 receptor agonists (RAs) and dual glucagon‐like peptide‐1 (GLP‐1)/glucose‐dependent insulinotropic polypeptide (GIP) RAs improve metabolic dysfunction associated with steatohepatitis (MASH) in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). We aimed to compare the estimate
Alex E. Henney, David R. Riley, Matthew Anson, Shazli Azmi, Uazman Alam, Daniel J. Cuthbertson   +5 more
wiley   +1 more source

Characterization and management of patients with hereditary factor X deficiency: A case series

Transfusion, Volume 65, Issue 10, Page 1786-1792, October 2025.
Abstract Background Hereditary factor X deficiency (HFXD) is an ultra‐rare, autosomal recessive bleeding disorder that results in reduced factor X coagulant activity (FX:C). HFXD is traditionally classified by severity as severe (FX:C <1%), moderate (FX:C = 1%–5%), or mild (FX:C = 6%–10%).
Meera Chitlur, Lauren E. Amos, Mark T. Reding, Cynthia Sabo, Suchitra S. Acharya   +4 more
wiley   +1 more source

Severe Pediatric Arterial Thrombosis in Antiphospholipid Syndrome and Systemic Lupus Erythematosus: A Case Report. [PDF]

Cureus
Jimenez I, Trelles Sanchez H, Gómez SS, Zuñiga González H, Llerena Vargas ME, Valverde Bonilla DGD, Valladares C.   +6 more
europepmc   +1 more source

Safety evaluation of the food enzyme thermomycolin from the genetically modified Trichoderma reesei strain AR‐201

EFSA Journal, Volume 23, Issue 10, October 2025.
Abstract The food enzyme thermomycolin (EC 3.4.21.65) is produced with the genetically modified Trichoderma reesei strain AR‐201 by AB Enzymes GmbH. The genetic modifications do not give rise to safety concerns. The food enzyme was considered free from viable cells of the production organism and its DNA.
EFSA Panel on Food Enzymes (FEZ), Holger Zorn, José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize L. M. Solano, Henk Van Loveren, Laurence Vernis, Ana Gomes, Magdalena Andryszkiewicz, Daniele Cavanna, Natália Kovalkovičová, Silvia Peluso, Yi Liu   +18 more
wiley   +1 more source

Acute fatty liver disease in full-term pregnancy: a case report and review of the literature. [PDF]

J Med Case Rep
Nguyen PN, Ho QN.
europepmc   +1 more source

Safety evaluation of the food enzyme chymosin from the genetically modified Trichoderma reesei strain DP‐Nyj88

EFSA Journal, Volume 23, Issue 10, October 2025.
Abstract The food enzyme chymosin (EC 3.4.23.4) is produced with the genetically modified Trichoderma reesei strain DP‐Nyj88 by Genencor International BV. The genetic modifications do not give rise to safety concerns. The food enzyme was considered free from viable cells of the production organism and its DNA.
EFSA Panel on Food Enzymes (FEZ), Holger Zorn, José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize L. M. Solano, Henk Van Loveren, Laurence Vernis, Ana Criado, Cristina Fernàndez‐Fraguas, Silvia Peluso, Yi Liu   +16 more
wiley   +1 more source

Effectiveness and safety of bivalirudin anticoagulation therapy in adult patients receiving extracorporeal membrane oxygenation: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Hu Y, Yu L, Yang W.
europepmc   +1 more source

Safety evaluation of the food enzyme cellulase from the non‐genetically modified Aspergillus niger strain AC 4‐984

EFSA Journal, Volume 23, Issue 10, October 2025.
Abstract The food enzyme cellulase (4‐(1,3;1,4)‐β‐d‐glucan 4‐glucanohydrolase; EC 3.2.1.4) is produced with the non‐genetically modified Aspergillus niger strain AC 4‐984 by Shin Nihon Chemical Co., Ltd. The food enzyme was considered free from viable cells of the production organism.
EFSA Panel on Food Enzymes (FEZ), Holger Zorn, José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize L.M. Solano, Henk Van Loveren, Laurence Vernis, Magdalena Andryszkiewicz, Daniele Cavanna, Natalia Kovalkovicova, Yi Liu   +16 more
wiley   +1 more source